EFALIZUMABUM
- Product Name
- EFALIZUMABUM
- CAS No.
- 214745-43-4
- Chemical Name
- EFALIZUMABUM
- Synonyms
- EFALIZUMABUM;Hu1124|||HU 1124;Efalizumab (anti-ITGAL);Research Grade Efalizumab;Research Grade Efalizumab(DHD41001)
- CBNumber
- CB72631887
- Formula Weight
- 0
- MOL File
- Mol file
EFALIZUMABUM Property
- form
- Liquid
- color
- Colorless to light yellow
Safety
- Hazardous Substances Data
- 214745-43-4(Hazardous Substances Data)
N-Bromosuccinimide Price
- Product number
- ATB0023424
- Product name
- EFALIZUMAB
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $497.29
- Updated
- 2021/12/16
EFALIZUMABUM Chemical Properties,Usage,Production
Description
Efalizumab, a humanized monoclonal antibody marketed for the treatment of psoriasis, is a full-length IgG1 antibody developed through a murine anti-human CD11a mAb. It is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Psoriasis is a disease mediated through inflammatory cells (primarily T-cells expressing CD4 or CD8 markers) and keratinocytes. CD11a is the alpha-chain LFA-1 (leukocyte function associate antigen; integrin family). It is expressed on the surface of Tlymphocytes and it binds to the intercellular cell adhesion molecules (ICAM-1, -2 and -3) on endothelial cells, monocytes, keratinocytes, fibroblasts, and activated lymphocytes. By blocking LFA-1 binding the ability of T cells to adhere, migrate and be activated is blunted. Studies in chimpanzee and murine animal models demonstrated that efalizumab down regulates the expression of LFA-1 on lymphocytes, prevents contact dermatitis to 2,4-dinitrofluorobenzene, increases skin and heart transplant survival. In the collagen-induced arthritis model it delays onset and decreases the severity of the arthritic condition. In a study of 498 patients, efalizumab treatment of 1 or 2 mg/kg/wk for 12 weeks provided, respectively, a 39 or 27% Psoriasis Area and Severity Score (PASI) improvement of ≥75%. By comparison, placebo provided a 2% improvement. It was further demonstrated that a second 12-week course could provide additional improvement. As dose increases, clearance decreases (dose 0.1 mg/kg: 322 ml/day/kg; dose 10 mg/kg: 6.6 mL/day/kg) with data suggesting saturation of clearance above 10 mg/mL. A pharmacokinetic model positively correlates number of circulating cells expressing CD11a with relative clearance. This blockade decreases the CD11a expressed on circulating lymphocytes to about 25% of their baseline levels in patients with plaque psoriasis. Efalizumab is formulated as a once-weekly subcutaneous injectable, dosed at 0.7 to 1 mg/kg/week. Although mild adverse events were noted such as headache, pain chills, nausea, and fever, these events generally decreased after one or two doses. The overall rate of infections was only 3% higher than the placebo-arm and no depletion of T-cells was noted.
Originator
XOMA (US)
Uses
Treatment of transplant rejections; antipsoriatic (immunomodulator monoclonal antibody which decreases the activation, migration, and adhesion of T-cells). hu1124; anti-CD11a.
brand name
Raptiva
in vivo
Efalizumab shows side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection[2].
EFALIZUMABUM Preparation Products And Raw materials
Raw materials
Preparation Products
EFALIZUMABUM Suppliers
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 400-6206333 13167063860
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 48457
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 17316404525 17316404525
- 209533805@qq.com
- Country
- China
- ProdList
- 9763
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 400-821-026
- Sales@sangon.com
- Country
- China
- ProdList
- 6710
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
- Tel
- 9785721070
- info@cellsciences.com
- Country
- China
- ProdList
- 6308
- Advantage
- 58
- Tel
- 18926165828
- Country
- CHINA
- ProdList
- 198
- Advantage
- 58
- Tel
- 18312220236
- Country
- CHINA
- ProdList
- 178
- Advantage
- 58
- Tel
- --
- Fax
- --
- Proteintech-CN@ptglab.com
- Country
- CHINA
- ProdList
- 6290
- Advantage
- 58